Newsroom

Sorted by: Latest

-

Resumen: Povofortay® (povorcitinib), aprobado en Europa como el primer tratamiento oral que se administra una vez al día para adultos con hidradenitis supurativa de moderada a grave

WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) anunció hoy que la Comisión Europea (CE) ha aprobado Povofortay® (povorcitinib) en dosis de 45 mg y 75 mg para el tratamiento de adultos con hidradenitis supurativa (HS) de moderada a grave que cumplan los criterios de elegibilidad. «La aprobación de Povofortay por parte de la Comisión Europea supone un hito importante para Incyte: impulsa uno de los principales motores de crecimiento de nuestro negocio y ofrece una nueva opción terap...
-

Citibank UK Regulatory Announcement: FRN Variable Rate Fix

LONDON--(BUSINESS WIRE)--  Re: Macquarie Group Limited   USD 23,000,000.00   MATURING: 24-Aug-2027   ISIN: XS2525178047     PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 24-Aug-2026 TO 24-Nov-2026 HAS BEEN FIXED AT 5.85 PCT   DAY BASIS: ACTUAL/360   INTEREST PAYABLE VALUE 24-Nov-2026 WILL AMOUNT TO: USD 343,770.06 PER USD 23,000,000.00 DENOMINATION  ...
-

TreeFrog Therapeutics Appoints James Sterling as Chief Financial Officer

BORDEAUX, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)--TreeFrog Therapeutics, a biotechnology company developing scalable cell therapies built on its proprietary C-Stem™ technology, today announced the appointment of James Sterling as Chief Financial Officer, effective November 1, 2026. James joins TreeFrog’s executive leadership team and reports to Mark Rothera, President and Chief Executive Officer. He oversees finance, investor relations and corporate development as the company enters its nex...
-

Advicenne Informs About the Ongoing Safeguard Procedure

PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases and neurological disorders, today informs its shareholders that, at the hearing held on 9 November 2026 before the Paris Commercial Court, the court has extended the observation period by six months, until 5 May 2027. The Company will continue to communicat...
-

OOG and the American Diabetes Association Announce Collaboration to Advance AI-Powered Diabetes Education for Healthcare Professionals

SANTA MONICA, Calif.--(BUSINESS WIRE)--OOG and the American Diabetes Association Announce Collaboration to Advance AI-Powered Diabetes Education for Healthcare Professionals...
-

Scrum Alliance and Pluralsight Partner to Develop Product Leaders for the Age of Change

DENVER--(BUSINESS WIRE)--Scrum Alliance, the global certifying body for scrum and agile practitioners, and Pluralsight, a leading technology learning platform, today announced a partnership to develop product leaders for the age of change. Through a new on-demand path to the Certified Scrum Product Owner (CSPO) credential, technology professionals can prepare with Pluralsight's on-demand CSPO exam prep path and earn their CSPO certification by passing the new Scrum Alliance CSPO exam. As AI res...
-

Deadline Alert: Lennar Corporation Shareholders Have Until January 11, 2027 to Seek Lead Plaintiff Appointment in Securities Fraud Lawsuit, The Law Offices of Frank R. Cruz Notes

LOS ANGELES--(BUSINESS WIRE)--The deadline for Lennar Corporation ("Lennar" or the "Company") (NYSE: LEN) investors to seek appointment as lead plaintiff in a securities class action lawsuit is January 11, 2027. The lawsuit was filed on behalf of investors who purchased or otherwise acquired Lennar Corporation securities from February 7, 2025 to October 2, 2026, inclusive. The Law Offices of Frank R. Cruz today reminded investors of the deadline in the case, Triggs v. Lennar Corporation et al.,...
-

Advicenne : information relative à la procédure de sauvegarde

PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth Paris ALDVI - FR0013296746), société pharmaceutique spécialisée dans le développement et la commercialisation de traitements innovants pour les personnes souffrant de maladies rénales rares et de maladies neurologiques, informe aujourd’hui ses actionnaires que lors de l’audience du 9 novembre 2026 devant le Tribunal des activités économiques de Paris, la cour a renouvelé la période d’observation de six mois, soit jusqu’au 5 mai...
-

Japanese Glass Manufacturer HARIO Launches Heatproof Glass Matcha Bowl in the U.S. With Traditional Japanese Teapot-Style Handle

EL SEGUNDO, Calif. & TOKYO--(BUSINESS WIRE)--HARIO released a heatproof glass Matcha bowl, featuring a traditional Japanese teapot-inspired side handle, a pouring spout, and a deep, rounded shape...
-

Ready or Not: Korn Ferry Finds One in Four CEO Successions Are Unprepared

LOS ANGELES--(BUSINESS WIRE)--Roughly one in four CEO successions lack preparedness according to new research from Korn Ferry (NYSE: KFY). The firm’s analysis of CEO successions across more than 3,600 S&P Global large- and mid-cap companies in 2025 linked insufficient readiness to greater likelihood of abrupt CEO departures, a lack of qualified internal candidates and less time for incoming CEOs to prepare for their role. As Korn Ferry’s report, The Readiness Gap, shows, having a CEO succes...